Alopecia - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Alopecia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Alopecia - Pipeline Review, H1 2015', provides an overview of the Alopecia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alopecia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alopecia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alopecia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Alopecia Overview 8
Therapeutics Development 9
Pipeline Products for Alopecia - Overview 9
Pipeline Products for Alopecia - Comparative Analysis 10
Alopecia - Therapeutics under Development by Companies 11
Alopecia - Therapeutics under Investigation by Universities/Institutes 13
Alopecia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Alopecia - Products under Development by Companies 17
Alopecia - Products under Investigation by Universities/Institutes 18
Alopecia - Companies Involved in Therapeutics Development 19
AndroScience Corporation 19
Bristol-Myers Squibb Company 20
C3 Jian, Inc 21
Follicum AB 22
Kuhnil Pharmaceutical Co., Ltd. 23
Lee's Pharmaceutical Holdings Limited 24
Panacea Biotec Limited 25
ProCertus BioPharm Inc. 26
Taisho Pharmaceutical Co., Ltd. 27
Tigo GmbH 28
Vida Therapeutics Inc. 29
Alopecia - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
abatacept (recombinant) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ASCJ-9 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
calcitriol - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DHL-HisZnNa - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
interferon beta-1b - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
KI-1104 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
KI-1105 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Peptide for Alopecia - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide for Alopecia and Chemotherapy Effects - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ProDermaCel - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Recombinant Peptides for Alopecia - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Proteins to Antagonize IFN-Gamma Receptor for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Activate P2Y5 Receptor for Alopecia - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
V-2248 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ZK-003 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Alopecia - Recent Pipeline Updates 60
Alopecia - Dormant Projects 63
Alopecia - Discontinued Products 65
Alopecia - Product Development Milestones 66
Featured News & Press Releases 66
Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables
Number of Products under Development for Alopecia, H1 2015 9
Number of Products under Development for Alopecia - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Alopecia - Pipeline by AndroScience Corporation, H1 2015 19
Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2015 20
Alopecia - Pipeline by C3 Jian, Inc, H1 2015 21
Alopecia - Pipeline by Follicum AB, H1 2015 22
Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 23
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 24
Alopecia - Pipeline by Panacea Biotec Limited, H1 2015 25
Alopecia - Pipeline by ProCertus BioPharm Inc., H1 2015 26
Alopecia - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 27
Alopecia - Pipeline by Tigo GmbH, H1 2015 28
Alopecia - Pipeline by Vida Therapeutics Inc., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Alopecia Therapeutics - Recent Pipeline Updates, H1 2015 60
Alopecia - Dormant Projects, H1 2015 63
Alopecia - Dormant Projects (Contd..1), H1 2015 64
Alopecia - Discontinued Products, H1 2015 65